High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance

被引:29
作者
Takeda, Keita [1 ,2 ]
Suzuki, Junko [1 ]
Watanabe, Akira [3 ]
Arai, Teppei [3 ]
Koiwa, Tomohiro [1 ]
Shinfuku, Kyota [1 ]
Narumoto, Osamu [1 ]
Kawashima, Masahiro [1 ]
Fukami, Takeshi [4 ]
Tamura, Atsuhisa [1 ]
Nagai, Hideaki [1 ]
Matsui, Hirotoshi [1 ]
Kamei, Katsuhiko [3 ]
机构
[1] Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, 3-1-1 Takeoka, Tokyo 2048585, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Basic Mycobacteriol, Nagasaki, Japan
[3] Chiba Univ, Med Mycol Res Ctr, Div Clin Res, Chiba, Japan
[4] Natl Hosp Org Tokyo Natl Hosp, Dept Thorac Surg, Tokyo, Japan
关键词
Aspergillus fumigatus; azole resistance; chronic pulmonary aspergillosis; cyp51A; hmg1; SUSCEPTIBILITY; GUIDELINES; MECHANISMS; DIAGNOSIS; UPDATE;
D O I
10.1093/mmy/myaa052
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The prevalence of azole-resistant Aspergillus fumigatus (ARAF) among chronic pulmonary aspergillosis (CPA) patients treated with azoles in Japan is unknown. The aim of this study was to determine the detection rate of ARAF in isolates from CPA patients who were treated with azoles for varying durations. The potential mechanism of acquiring resistance was examined by sequencing cyp51A and hmg1, two genes associated with ARAF. A. fumigatus isolates (n = 120) were collected from CPA patients (n = 104) between February 2012 and February 2019, at National Hospital Organization Tokyo National Hospital. The isolates were tested for susceptibility to the azole drugs itraconazole (ITCZ) and voriconazole (VRCZ). The detection rate of ARAF among all isolates was 8.3% (n = 10). Of the 10 resistant isolates, eight were ITCZ-resistant and five were VRCZ-resistant. Among 47 isolates obtained from 36 CPA patients who were treated with ITCZ (for an average of 256 days) and/or VRCZ (for an average of 29 days), the resistance rates were 17.0% and 10.6%, respectively. In addition, 46.2% of 13 isolates obtained from CPA patients with ongoing azole treatment at the time of antifungal therapy failure were resistant to azoles. Among the 10 ARAF isolates, a point mutation was detected in cyp51A in seven isolates and in hmg1 in two isolates. ARAF was detected at a high rate in CPA patients, particularly in those with ongoing long-term azole treatment, at the time of azole antifungal therapy failure. Lay Summary Aspergillus fumigatus can acquire azole resistance during long-term treatment with azole drugs in patients with chronic pulmonary aspergillosis (CPA). The aim of this study was to determine the detection rate of azole-resistant A. fumigatus (ARAF) in isolates from CPA patients who had been treated with azoles. In addition, a potential mechanism of acquiring resistance was examined by sequencing cyp51A and hmg1, two genes associated with ARAF. A. fumigatus isolates (n = 120) were collected from CPA patients (n = 104). The isolates were tested for susceptibility to the azole drugs itraconazole (ITCZ) and voriconazole (VRCZ). The detection rate of ARAF from all isolates was 8.3% (n = 10). Greater than 10% of the 47 isolates obtained from 36 CPA patients who had been treated with azoles exhibited resistance. Furthermore, 46.2% of 13 isolates obtained from CPA patients with ongoing azole treatment at the time of antifungal therapy failure were resistant to azoles. Among the 10 ARAF isolates, a point mutation was detected in cyp51A in seven isolates and in hmg1 in two isolates. ARAF was detected at a high rate in CPA patients undergoing long-term azole treatment at the time of antifungal therapy failure.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 37 条
[21]   Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America [J].
Patterson, Thomas F. ;
Thompson, George R., III ;
Denning, David W. ;
Fishman, Jay A. ;
Hadley, Susan ;
Herbrecht, Raoul ;
Kontoyiannis, Dimitrios P. ;
Marr, Kieren A. ;
Morrison, Vicki A. ;
Nguyen, M. Hong ;
Segal, Brahm H. ;
Steinbach, William J. ;
Stevens, David A. ;
Walsh, Thomas J. ;
Wingard, John R. ;
Young, Jo-Anne H. ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2016, 63 (04) :E1-E60
[22]   Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity [J].
Rajendran, Ranjith ;
Mowat, Eilidh ;
McCulloch, Elaine ;
Lappin, David F. ;
Jones, Brian ;
Lang, Sue ;
Majithiya, Jayesh B. ;
Warn, Peter ;
Williams, Craig ;
Ramage, Gordon .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) :2092-2097
[23]   Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism [J].
Snelders, Eveline ;
van der Lee, Henrich A. L. ;
Kuijpers, Judith ;
Rijs, Anthonius J. M. M. ;
Varga, Janos ;
Samson, Robert A. ;
Mellado, Emilia ;
Donders, A. Rogier T. ;
Melchers, Willem J. G. ;
Verweij, Paul E. .
PLOS MEDICINE, 2008, 5 (11) :1629-1637
[24]   Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus [J].
Snelders, Eveline ;
Camps, Simone M. T. ;
Karawajczyk, Anna ;
Schaftenaar, Gijs ;
Kema, Gert H. J. ;
van der Lee, Henrich A. ;
Klaassen, Corne H. ;
Melchers, Willem J. G. ;
Verweij, Paul E. .
PLOS ONE, 2012, 7 (03)
[25]   Species identification, antifungal susceptibility, and clinical feature association of Aspergillus section Nigri isolates from the lower respiratory tract [J].
Takeda, Keita ;
Suzuki, Junko ;
Watanabe, Akira ;
Matsuki, Mei ;
Higa, Katsuyuki ;
Inoue, Eri ;
Akashi, Shunsuke ;
Shimada, Masahiro ;
Kawashima, Masahiro ;
Ohshima, Nobuharu ;
Fukami, Takeshi ;
Masuda, Kimihiko ;
Yamane, Akira ;
Tamura, Atsuhisa ;
Nagai, Hideaki ;
Matsui, Hirotoshi ;
Tohma, Shigeto ;
Kamei, Katsuhiko .
MEDICAL MYCOLOGY, 2020, 58 (03) :310-314
[26]   Correlation between Triazole Treatment History and Susceptibility in Clinically Isolated Aspergillus fumigatus [J].
Tashiro, Masato ;
Izumikawa, Koichi ;
Hirano, Katsuji ;
Ide, Shotaro ;
Mihara, Tomo ;
Hosogaya, Naoki ;
Takazono, Takahiro ;
Morinaga, Yoshitomo ;
Nakamura, Shigeki ;
Kurihara, Shintaro ;
Imamura, Yoshifumi ;
Miyazaki, Taiga ;
Nishino, Tomoya ;
Tsukamoto, Misuzu ;
Kakeya, Hiroshi ;
Yamamoto, Yoshihiro ;
Yanagihara, Katsunori ;
Yasuoka, Akira ;
Tashiro, Takayoshi ;
Kohno, Shigeru .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) :4870-4875
[27]   Antifungal Susceptibilities of Aspergillus fumigatus Clinical Isolates Obtained in Nagasaki, Japan [J].
Tashiro, Masato ;
Izumikawa, Koichi ;
Minematsu, Asuka ;
Hirano, Katsuji ;
Iwanaga, Naoki ;
Ide, Shotaro ;
Mihara, Tomo ;
Hosogaya, Naoki ;
Takazono, Takahiro ;
Morinaga, Yoshitomo ;
Nakamura, Shigeki ;
Kurihara, Shintaro ;
Imamura, Yoshifumi ;
Miyazaki, Taiga ;
Nishino, Tomoya ;
Tsukamoto, Misuzu ;
Kakeya, Hiroshi ;
Yamamoto, Yoshihiro ;
Yanagihara, Katsunori ;
Yasuoka, Akira ;
Tashiro, Takayoshi ;
Kohno, Shigeru .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :584-587
[28]   Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward [J].
Tashiro, Takayoshi ;
Izumikawa, Koichi ;
Tashiro, Masato ;
Takazono, Takahiro ;
Morinaga, Yoshitomo ;
Yamamoto, Kazuko ;
Imamura, Yoshifumi ;
Miyazaki, Taiga ;
Seki, Masafumi ;
Kakeya, Hiroshi ;
Yamamoto, Yoshihiro ;
Yanagihara, Katsunori ;
Yasuoka, Akira ;
Kohno, Shigeru .
MEDICAL MYCOLOGY, 2011, 49 (06) :581-587
[29]   Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan [J].
Toyotome, Takahito ;
Saito, Shunpei ;
Koshizaki, Yusuke ;
Komatsu, Ryoichi ;
Matsuzawa, Tetsuhiro ;
Yaguchi, Takashi .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (02) :321-323
[30]   Azole susceptibility in clinical and environmental isolates of Aspergillus fumigatus from eastern Hokkaido, Japan [J].
Toyotome, Takahito ;
Fujiwara, Takayuki ;
Kida, Hideyuki ;
Matsumoto, Munehiro ;
Wada, Terumi ;
Komatsu, Ryoichi .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (9-10) :648-650